ReviewFrontiers in immunology2025
Chemokines in the resolution of inflammation: key players and targets for therapeutic modulation.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Evasins: Biology and Therapeutic Potential of Broad-Spectrum Chemokine Inhibitors.Basic & clinical pharmacology & toxicology · 2026Review
- A Cell-Based Therapeutic Strategy for Stress Urinary Incontinence: Functional and Molecular Evidence from Decidua-Derived Mesenchymal Stromal Cells.International journal of molecular sciences · 2026Article
- Metabolic Mechanisms of Neutrophil Phagocytic Activity in Patients with Widespread Purulent Peritonitis Bacterial Peritonitis Before and After Surgery.International journal of molecular sciences · 2026Article
- The role of chemokine receptors in leukemia: implications for prognosis and therapeutic strategies.Molecular biology reports · 2026Review
- Dual CD73/AFrontiers in pharmacology · 2026Article
- Decoding Chronicity: Oxidative Stress and Inflammation as Systems Hubs.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The resolution of inflammation is an active, tightly regulated process essential for restoring tissue homeostasis after an inflammatory process. While chemokines are classically recognized for their roles in leukocyte recruitment and immune cell positioning during the onset of inflammation, emerging evidence highlights their pivotal functions in orchestrating the resolution phase, as well. The chemokine system contributes to inflammation resolution through several complementary mechanisms, including the depletion of pro-inflammatory chemokines, the generation of autoantibodies, the promotion of neutrophil reverse migration, the recruitment and polarization of pro-resolving immune cells such as macrophages and regulatory T cells, and the induction of tissue repair and disease recovery. Modulating chemokine-receptor interactions, enhancing the activity of pro-resolving chemokines, or blocking detrimental chemokine signaling pathways represent promising strategies for the treatment of excessive inflammation or chronic inflammatory diseases. In addition, modulation of glycosaminoglycan interactions or chemokine-modifying enzymes, might also be useful in this context. In this review, we explore the roles of chemokines in resolution, with a focus on their mechanistic contributions to immune modulation and their potential as therapeutic targets for restoring immune balance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.